Simcere Pharmaceutical misses Q2 estimates, stock dips

|About: Simcere Pharmaceutical Group (SCR)|By:, SA News Editor

Simcere Pharmaceutical (SCR -0.7%) slips after its Q2 earnings miss on both EPS and revenue estimates.

Total revenue slid 3% Y/Y, negatively impacted by the government's pricing policy, government restrictions on the use of antibiotics and market competition.

Gross margin from continuing operations decreased to 83.1%, compared to 84.5% for the same period in 2012.